Free Trial

Savara (SVRA) Competitors

Savara logo
$2.86 -0.07 (-2.22%)
As of 12:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SVRA vs. LGND, HRMY, BLTE, KNSA, ARWR, GMTX, TVTX, FOLD, SUPN, and SDGR

Should you be buying Savara stock or one of its competitors? The main competitors of Savara include Ligand Pharmaceuticals (LGND), Harmony Biosciences (HRMY), Belite Bio (BLTE), Kiniksa Pharmaceuticals (KNSA), Arrowhead Pharmaceuticals (ARWR), Gemini Therapeutics (GMTX), Travere Therapeutics (TVTX), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical preparations" industry.

Savara vs.

Ligand Pharmaceuticals (NASDAQ:LGND) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, community ranking, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 5.9% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Savara had 7 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 11 mentions for Savara and 4 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.33 beat Savara's score of 0.76 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ligand Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Savara
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ligand Pharmaceuticals received 253 more outperform votes than Savara when rated by MarketBeat users. Likewise, 70.39% of users gave Ligand Pharmaceuticals an outperform vote while only 66.89% of users gave Savara an outperform vote.

CompanyUnderperformOutperform
Ligand PharmaceuticalsOutperform Votes
554
70.39%
Underperform Votes
233
29.61%
SavaraOutperform Votes
301
66.89%
Underperform Votes
149
33.11%

Ligand Pharmaceuticals has a net margin of 29.68% compared to Savara's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 4.95% beat Savara's return on equity.

Company Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals29.68% 4.95% 4.39%
Savara N/A -58.89%-46.44%

Ligand Pharmaceuticals has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Savara has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500.

Ligand Pharmaceuticals has higher revenue and earnings than Savara. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ligand Pharmaceuticals$181.49M10.77$52.15M-$7.12-14.23
SavaraN/AN/A-$54.70M-$0.48-6.10

Ligand Pharmaceuticals currently has a consensus target price of $146.14, suggesting a potential upside of 44.28%. Savara has a consensus target price of $8.83, suggesting a potential upside of 201.48%. Given Savara's higher probable upside, analysts clearly believe Savara is more favorable than Ligand Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Savara
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Summary

Ligand Pharmaceuticals beats Savara on 14 of the 17 factors compared between the two stocks.

Get Savara News Delivered to You Automatically

Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SVRA vs. The Competition

MetricSavaraPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$506.41M$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-6.819.0626.8019.71
Price / SalesN/A251.66397.78120.67
Price / CashN/A65.8538.2534.62
Price / Book2.826.456.774.50
Net Income-$54.70M$143.98M$3.23B$248.22M
7 Day Performance-4.56%0.38%0.48%-0.78%
1 Month Performance-9.85%2.14%9.13%11.53%
1 Year Performance-29.74%-0.33%18.58%8.99%

Savara Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SVRA
Savara
1.6375 of 5 stars
$2.87
-2.2%
$8.83
+208.3%
-32.3%$495.18MN/A-6.66N/ANews Coverage
Gap Down
LGND
Ligand Pharmaceuticals
4.3412 of 5 stars
$106.38
+1.8%
$146.14
+37.4%
+16.1%$2.05B$181.49M42.3880Positive News
HRMY
Harmony Biosciences
4.7815 of 5 stars
$35.65
+4.7%
$52.33
+46.8%
+13.1%$2.05B$744.85M16.90200Positive News
BLTE
Belite Bio
2.0381 of 5 stars
$61.99
+1.5%
$96.67
+55.9%
+43.5%$1.97BN/A-55.8510Analyst Downgrade
Analyst Revision
KNSA
Kiniksa Pharmaceuticals
2.9162 of 5 stars
$26.84
+3.1%
$38.80
+44.6%
+34.7%$1.95B$481.17M-191.70220Positive News
Insider Trade
ARWR
Arrowhead Pharmaceuticals
3.51 of 5 stars
$13.97
+7.2%
$41.44
+196.7%
-38.8%$1.92B$2.50M-2.70400News Coverage
Analyst Forecast
Analyst Revision
GMTX
Gemini Therapeutics
N/A$44.24
-0.1%
N/A+56.4%$1.92BN/A-44.2430News Coverage
TVTX
Travere Therapeutics
2.9573 of 5 stars
$21.54
+7.6%
$31.79
+47.6%
+139.3%$1.91B$273.53M-5.25460Positive News
Gap Down
FOLD
Amicus Therapeutics
3.9848 of 5 stars
$6.21
+3.8%
$16.22
+161.2%
-35.6%$1.91B$543.14M-34.50480Positive News
High Trading Volume
SUPN
Supernus Pharmaceuticals
2.6215 of 5 stars
$32.15
+1.4%
$36.00
+12.0%
+15.0%$1.80B$668.00M30.05580Positive News
SDGR
Schrödinger
2.9309 of 5 stars
$24.17
+1.1%
$32.80
+35.7%
-6.3%$1.77B$207.54M-10.33790News Coverage

Related Companies and Tools


This page (NASDAQ:SVRA) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners